Director Christopher Patusky filed a Form 144 notice on November 9, 2026, disclosing a proposed sale of 1,210 shares of United Therapeutics Corporation common stock acquired through a stock option exercise.

Key Highlights

  • Seller: Christopher Patusky, a Director of United Therapeutics Corporation
  • Shares proposed for sale: 1,210 shares of common stock
  • Aggregate market value: $701,800.00
  • Acquisition method: Stock option exercise from the issuer, dated November 9, 2026, with cash payment
  • Shares outstanding: 42,588,726 shares of common stock
  • Broker named: Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004
  • Prior three-month sales: Nothing to report

Patusky Form 144 Filing: Stock Option Exercise and Proposed Sale Details

According to the filing, Christopher Patusky, identified as a Director of United Therapeutics Corporation (NASDAQ:UTHR), submitted a Form 144 notice dated November 9, 2026, disclosing his intent to sell 1,210 shares of the company's common stock. The filing lists the aggregate market value of the shares proposed for sale at $701,800.00. The approximate date of sale listed in the notice is November 9, 2026, with the named exchange identified as NASDAQ.

The filing discloses that the 1,210 shares were acquired on November 9, 2026, through a stock option exercise from the issuer, with cash listed as the nature of payment. No prior sales of United Therapeutics securities during the three months preceding the notice were reported by the filer. The filing states that as of the notice date, 42,588,726 shares of United Therapeutics common stock were outstanding.

As required by Form 144, Patusky represented by signing the notice "that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed." The filing does not indicate whether a Rule 10b5-1 written trading plan was adopted in connection with this proposed sale.

What Was Disclosed

Director Christopher Patusky filed a Form 144 notice proposing to sell 1,210 shares of United Therapeutics Corporation common stock, acquired via stock option exercise on November 9, 2026, with an aggregate market value of $701,800.00 and no prior sales in the past three months.